The "hallmarks of aging" framework, nine distinct biological processes that collectively produce the phenotype we call aging, has become the organising principle for serious longevity research. Telomere shortening, mitochondrial dysfunction, cellular senescence, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, stem cell exhaustion, altered intercellular communication, and genomic instability. Each hallmark is a potential intervention target. Each intervention requires different tools.
Peptides address several of these hallmarks directly. The longevity stack concept is the application of multiple compounds simultaneously to address multiple hallmarks, not because any single compound is a silver bullet, but because aging is a multi-system process that benefits from a multi-mechanism approach.
What the evidence actually supports
Before the compounds: an honest grounding. The longevity peptide space sits at the intersection of compelling mechanistic science and limited human clinical data. The animal data, particularly for Epithalon, GHK-Cu, and MOTS-c, is extensive and consistent. The human data is thin. No randomised controlled trial has demonstrated that any longevity peptide stack extends human lifespan or even meaningfully slows age-related biomarker decline.
What exists is: mechanism data (these compounds do specific things at the cellular level, reliably), biomarker data (some compounds improve measurable indicators of aging in humans), and outcome data in long-lived animal models (Epithalon has produced the most extensive longevity data in this category). The gap between animal data and human proof is the central honest caveat in this entire field.
A 2026 Frontiers in Aging review identified nine peptides spanning diverse aging interventions, metabolic restoration, telomere biology, dermal regeneration, tissue repair, neuroprotection, and GH modulation, and concluded that mechanistically diverse approaches to multiple aging hallmarks represent the frontier of gerontological peptide medicine. This is the scientific basis for the stack concept. It is not proof that stacks work, it is a mechanistic rationale for studying them.
The four biological systems and the compounds that address them
1. Telomere integrity, Epithalon
Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division. Critically short telomeres trigger cellular senescence or apoptosis. Telomerase is the enzyme that adds sequence to telomere ends, active in germline cells and stem cells, largely suppressed in somatic cells. Activating telomerase in somatic cells to slow telomere shortening is the central mechanistic target.
Epithalon is a synthetic tetrapeptide derived from Epithalamin, the natural pineal peptide extract. In 2025, an independent laboratory (outside the Khavinson Institute that developed Epithalon) confirmed telomere elongation in human cell lines for the first time, a meaningful external validation of the core claimed mechanism. The clinical protocol from the original research: 10mg daily for 10 consecutive days, subcutaneous, repeated 2–4 times per year.
Epithalon also regulates pineal gland function and melatonin production, particularly relevant as the pineal gland calcifies with age and melatonin output declines. This gives it a secondary sleep and circadian rhythm application that most longevity protocols use as a practical benefit marker even when the telomere effects are not directly measurable.
2. Mitochondrial function, MOTS-c and SS-31
Mitochondrial dysfunction is one of the most well-characterised hallmarks of aging. Mitochondria produce energy (ATP) and regulate cellular metabolism, their decline in number and function with age contributes directly to fatigue, metabolic slowdown, and reduced cellular repair capacity.
MOTS-c is a 16-amino acid peptide encoded within mitochondrial DNA, a discovery that redefined our understanding of mitochondria as active signalling organs rather than passive energy producers. Skeletal muscle produces 12 times more MOTS-c during exercise than at rest; circulating levels decline with age. It activates AMPK (the cellular energy sensor), improves insulin sensitivity, and in mouse studies extends healthy lifespan and reverses age-related metabolic decline. Protocol: 5–10mg twice weekly, with periodic cycling.
SS-31 (Elamipretide) targets the inner mitochondrial membrane, specifically cardiolipin, which is essential for electron transport chain efficiency. Unlike MOTS-c which works at the signalling level, SS-31 addresses mitochondrial structural integrity. It reduces mitochondrial oxidative stress and has completed Phase 2 trials in heart failure and kidney injury. The combination of MOTS-c (metabolic signalling) + SS-31 (structural efficiency) represents the most comprehensive mitochondrial targeting approach available.
3. Cellular repair and gene expression, GHK-Cu and NAD+
GHK-Cu's gene expression data is the most remarkable finding in the skin and longevity peptide literature. Research by Loren Pickart showed GHK-Cu modulates over 4,000 human genes, shifting expression patterns toward those observed in younger cells. It upregulates collagen, elastin, and wound healing genes while downregulating inflammatory and cancer-associated pathways. Plasma levels decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60.
NAD+ is the coenzyme that sits at the centre of cellular energy metabolism, DNA repair, and sirtuin activation (the longevity proteins). NAD+ levels decline 50% between young adulthood and age 60. Precursors NMN and NR restore NAD+ via different biosynthetic pathways, NMN more directly, NR more bioavailable orally. The human trial data is the strongest of any longevity supplement category, with multiple RCTs showing consistent NAD+ restoration at 250–500mg NMN or NR daily.
4. GH axis restoration, CJC-1295/Ipamorelin or Sermorelin
Growth hormone secretion declines significantly with age, GH pulse amplitude and frequency both decrease, contributing to body composition changes, reduced recovery, declining skin quality, and diminished sleep architecture. GH secretagogue stacks address this decline by amplifying the pituitary's own GH release rather than introducing exogenous hormone.
The before-bed protocol is critical, the body's largest natural GH pulse occurs in the first hours of slow-wave sleep, and CJC-1295/Ipamorelin timed to bedtime amplifies this pulse while preserving the pituitary's own regulatory feedback. Sermorelin offers the same mechanism with a prior FDA approval history, making it more accessible through compounding pharmacies.
The practical protocol, how serious longevity stacks are actually run
Longevity peptide protocols require cycle discipline. Continuous uninterrupted use of most compounds risks receptor downregulation and diminishing returns. The established cycling structures from clinical practice and the research literature:
Epithalon: 10 days on / 4 months off. Maximum 3 cycles per year. Standalone, not concurrent with other peptides.
MOTS-c: 20 days on / 4 months off.
GHK-Cu (injectable): 30 days on / 30 days off.
CJC-1295/Ipamorelin: 8 weeks on / 8 weeks off. 5 days/week administration.
NAD+ (oral NMN or NR): Daily, no cycling required.
SS-31: 12 weeks on / 4 weeks off.
The cycling structure matters not just for efficacy but for monitoring. Bloodwork before, during, and after each cycle is the only way to know whether interventions are producing measurable biomarker changes. At minimum: IGF-1 (for GH axis compounds), full metabolic panel, inflammatory markers (hsCRP, IL-6), and compound-specific markers where available.
Who this is actually for
The longevity peptide stack is not a starting point. It's an advanced protocol appropriate for people who have: optimised the fundamentals (sleep, exercise, nutrition, stress management), are working with a physician familiar with longevity medicine, have baseline bloodwork to track against, and have a realistic timeline, longevity interventions work over years, not weeks.
The Bryan Johnson effect has created unrealistic expectations about timelines. The biological processes these compounds target, telomere length, mitochondrial density, NAD+ levels, change slowly and require consistent long-term intervention to produce measurable differences. Anyone expecting dramatic changes over a 12-week cycle is misunderstanding what these compounds are for.